A new treatment option for patients with peripheral T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination treatment for peripheral T-cell lymphoma, a type of blood cancer. It may help patients who cannot tolerate standard chemotherapy or whose disease has come back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have peripheral T-cell lymphoma, but not NK/T-cell lymphoma.
- You are either newly diagnosed, or your disease has returned or not responded to treatment.
- You are unable to tolerate standard chemotherapy, for example because of age or other health reasons.
- You are 18 years or older.
- Your blood counts and organ function are within acceptable ranges.
- You have not had recent major surgery, bleeding, or infections such as AIDS, syphilis, or active hepatitis B or C.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (bendamustine, chidamide, and lenalidomide) for patients with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to see if this new combination can help when standard treatments have failed.
This trial tests a combination of two drugs, chidamide and golidocitinib, for peripheral T-cell lymphoma that has come back or not responded to earlier treatments. The goal is to see if this combination can help shrink or control the lymphoma.
This trial studies whether adding chidamide to a combination chemotherapy plan (azacitidine, liposomal mitoxantrone, and prednisone) works better for people newly diagnosed with nodal T-follicular helper (TFH) cell lymphoma. It’s testing a treatment strategy after diagnosis to improve disease control and outcomes.
This trial tests a combination of two targeted drugs, Chidamide and Duvalisib, for people with peripheral T-cell lymphoma or NK/T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this drug combination can help shrink or control the lymphoma.
This Phase 2 trial tests whether combining sintilimab (an immunotherapy) with chidamide (an anticancer “epigenetic” drug) can shrink peripheral T-cell lymphoma that has come back or didn’t respond. It’s for adults who have measurable lymphoma spots and can safely take both medicines.
This trial tests two pills—linperlisib and chidamide—for people with a type of lymphoma called PTCL. The combination might work better together than either alone.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.